A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s

OBJECTIVE: Our main aim was to investigate the effect of a single oral dose of C21, a selective angiotensin II type 2 receptor agonist, on cold-induced vasoconstriction in SSc-related RP. METHODS: This was a phase IIa, randomized, double-blind, cross-over, single-dose, placebo-controlled, single-cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrick, Ariane L, Batta, Rohit, Overbeck, Kamilla, Raud, Johan, Manning, Joanne, Murray, Andrea, Dinsdale, Graham, Tornling, Göran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891408/
https://www.ncbi.nlm.nih.gov/pubmed/35894657
http://dx.doi.org/10.1093/rheumatology/keac426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891408/
https://www.ncbi.nlm.nih.gov/pubmed/35894657
http://dx.doi.org/10.1093/rheumatology/keac426

Ejemplares similares